Literature DB >> 17655344

How shall we use the proteomics toolbox for biomarker discovery?

Pierre Lescuyer1, Denis Hochstrasser, Thierry Rabilloud.   

Abstract

Biomarker discovery for clinical purposes is one of the major areas in which proteomics is used. However, despite considerable effort, the successes have been relatively scarce. In this perspective paper, we try to highlight and analyze the main causes for this limited success, and to suggest alternate strategies, which will avoid them, without eluding the foreseeable weak points of these strategies. Two major strategies are analyzed, namely, the switch from body fluids to cell and tissues for the initial biomarker discovery step or, if body fluids must be analyzed, the implementation of highly selective protein selection strategies.

Mesh:

Substances:

Year:  2007        PMID: 17655344     DOI: 10.1021/pr0702060

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  26 in total

Review 1.  The future of biological mass spectrometry.

Authors:  Marvin L Vestal
Journal:  J Am Soc Mass Spectrom       Date:  2011-04-09       Impact factor: 3.109

2.  Protein identification and quantification by two-dimensional infrared spectroscopy: implications for an all-optical proteomic platform.

Authors:  Frédéric Fournier; Elizabeth M Gardner; Darek A Kedra; Paul M Donaldson; Rui Guo; Sarah A Butcher; Ian R Gould; Keith R Willison; David R Klug
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-01       Impact factor: 11.205

3.  Enhanced information output from shotgun proteomics data by protein quantification and peptide quality control (PQPQ).

Authors:  Jenny Forshed; Henrik J Johansson; Maria Pernemalm; Rui M M Branca; Annsofi Sandberg; Janne Lehtiö
Journal:  Mol Cell Proteomics       Date:  2011-07-06       Impact factor: 5.911

4.  Apolipoprotein A1 and C-terminal fragment of α-1 antichymotrypsin are candidate plasma biomarkers associated with acute renal allograft rejection.

Authors:  Mary E Ziegler; Tingchao Chen; James F LeBlanc; Xuelian Wei; David W Gjertson; Ker-Chau Li; Mazdak A Khalighi; Charles R Lassman; Jeffrey L Veale; H Albin Gritsch; Elaine F Reed
Journal:  Transplantation       Date:  2011-08-27       Impact factor: 4.939

5.  Performance comparisons of nano-LC systems, electrospray sources and LC-MS-MS platforms.

Authors:  Qian Liu; Jennifer S Cobb; Joshua L Johnson; Qi Wang; Jeffrey N Agar
Journal:  J Chromatogr Sci       Date:  2013-01-17       Impact factor: 1.618

Review 6.  Exosomes in bodily fluids are a highly stable resource of disease biomarkers.

Authors:  Stephanie Boukouris; Suresh Mathivanan
Journal:  Proteomics Clin Appl       Date:  2015-03-19       Impact factor: 3.494

7.  Mass spectrometry in cancer biomarker research: a case for immunodepletion of abundant blood-derived proteins from clinical tissue specimens.

Authors:  Darue A Prieto; Donald J Johann; Bih-Rong Wei; Xiaoying Ye; King C Chan; Dwight V Nissley; R Mark Simpson; Deborah E Citrin; Crystal L Mackall; W Marston Linehan; Josip Blonder
Journal:  Biomark Med       Date:  2014       Impact factor: 2.851

Review 8.  Quality assessment for clinical proteomics.

Authors:  David L Tabb
Journal:  Clin Biochem       Date:  2012-12-12       Impact factor: 3.281

Review 9.  Proteomics and opportunities for clinical translation in urological disease.

Authors:  Ali R Vaezzadeh; Hanno Steen; Michael R Freeman; Richard S Lee
Journal:  J Urol       Date:  2009-07-17       Impact factor: 7.450

10.  A mouse model repository for cancer biomarker discovery.

Authors:  Karen S Kelly-Spratt; A Erik Kasarda; Mark Igra; Christopher J Kemp
Journal:  J Proteome Res       Date:  2008-07-15       Impact factor: 4.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.